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Abstract : Background 
The comparative effectiveness of commonly - used conservative treatments 
for carpal tunnel syndrome (CTS) has not been evaluated previously in 
primary care . This trial compared the clinical and cost - effectiveness , of 
night splints and a corticosteroid injection for reducing symptoms and 
improving hand function in patients with mild/moderate CTS . 
Methods 
We completed a multicentre , randomised , open label , pragmatic , trial in 
adults with mild/moderate CTS recruited from primary and community 
musculoskeletal clinics services . Patients aged 18 years and over with a 
new episode of idiopathic mild/moderate CTS of at least 6 weeks duration 
were eligible . Randomisation was on a 1 : 1 ratio (permutated blocks of 2 
and 4 by site) , and was completed using an online web or third party 
telephone service , to receive either ; a single injection of 20mg 
Methylprednisolone Acetate (from 40mg/ml) , or a night - resting splint to 
be worn for 6 weeks . Patients and clinicians could not be masked to 
intervention . The primary outcome was the overall score of the Boston 
Carpal Tunnel Questionnaire (BCTQ) at 6 weeks . Analysis was by intention -
to - treat with multiple imputation for missing data conducted blind to 
treatment group allocation. The trial is closed to new participants 
(Eu draCT number : 2013 - 001435 - 48) . 
Findings 
Between 17th April 2015 and 31st December 2017 , 234 participants from 25 
recruiting sites were randomised , (splint n=118 , injection n=116) , of 
whom 212 (90.6%) completed 6- week primary outcome data . The BCTQ score 
was significantly better at 6 weeks in the injection arm compared with 
the splint arm (mean 2 . 02 vs . 2 . 29 ; adjusted mean difference - 0 . 32 (95% 
confidence interval - 0 . 48 , - 0 . 16)) . No adverse events were reported 
Interpretation 
A single corticosteroid injection shows superior clinical effectiveness 
at 6 weeks compared with night - resting splints , making it the treatment 
of choice for rapid symptom response in mild/moderate CTS presenting in 
primary care . 
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28 SUMMARY 
29 Background 
30 The comparative effectiveness of commonly-used conservative treatments for carpal tunnel 
31 syndrome (CTS) has not been evaluated previously in primary care. This trial compared the 
32 clinical and cost-effectiveness, of night splints and a corticosteroid injection fo r reducing 
33 symptoms and improving hand function in patients with mild/moderate CTS. 
34 Methods 
35 We completed a multicentre, randomised, open label , pragmatic, trial in adults with 
36 mild/moderate CTS recruited from primary and community musculoskeletal clinics services. 
37 Patients aged I8 years and over with a new episode of idiopathic mild/moderate CTS of at 
38 least 6 weeks duration were eligible. Randomisation was on a I: I ratio (permutated blocks of 
39 2 and 4 by site), and was completed using an online web or third party telephone service, to 
40 receive either; a single injection of20mg Methylprednisolone Acetate (from 40mg/ml), or a 
41 night-resting splint to be worn for 6 weeks. Patients and clinicians could not be masked to 
42 intervention. The primary outcome was the overall score of the Boston Carpal Tunnel 
43 Questionnaire (BCTQ) at 6 weeks. Analysis was by intention-to-treat with multiple 
44 imputation for missing data conducted blind to treatment group allocation. The trial is closed 
45 to new participants (EudraCT number: 20 I3-00 I435-48). 
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46 
47 Findings 
48 Between I i 11 April 2015 and 31 51 December 2017, 234 participants from 25 recruiting sites 
49 were randomised , (splint n= ll8 , injection n= 116), ofwhom 212 (90.6%) completed 6-week 
50 primary outcome data. The BCTQ score was significantly better at 6 weeks in the injection 
51 arm compared with the splint am1 (mean 2.02 vs. 2.29; adjusted mean difference -0 .32 (95% 
52 confidence interval -0.48 , -0.16)) . No adverse events were reported 
53 Interpretation 
54 A single corticosteroid injection shows superior clinical effectiveness at 6 weeks compared 
55 with night-resting splints, making it the treatment of choice for rapid symptom response in 
56 mild/moderate CTS presenting in primary care. 
57 Trial registration: EudraCT number 2013-001435-48- The clinical and cost effectiveness of a 
58 steroid injection versus a night splint for Carpal Tunnel Syndrome: a pragmatic randomised 
59 trial in primary care 
60 Funding 
61 Arthritis Research UK (Grant Number 20105) 
62 
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63 Keywords: Carpal Tunnel Syndrome, Boston carpal tunnel questionnaire, night splints, 
64 corticosteroid injection, randomised clinical trial , protocol 
65 
66 Background 
67 Carpal tunnel syndrome (CTS) is the most common compression neuropathy affecting the 
68 upper limb, resulting from entrapment of the median nerve in the carpal tunnel.' CTS 
69 adversely affects daily activities, limi ts work capacity and impacts on general health and 
70 quality of life.2,3 In a primary care population, prevalence is reported to be 36.1 per I 0,000 
71 with incidence rates per 10,000 per year of 19.12 for men and 35.95 for women~ 
72 Classically, CTS causes discomfot1, paraesthesia, and numbness in the median nerve 
73 distribution. Nocturnal symptoms are often significant causing sleep disturbance, and 
74 bilateral symptoms occur in over 50% ofpatients. 2 In primary care, diagnosis is based on 
75 clinical history and examination findings6 with electrophysiological diagnostic tests requested 
76 when a clinical diagnos is cannot be determined, and for severe cases where surgical 
. .d d 7 77 management ts const ere . 
78 There is no consensus on the best primary care management of mild /moderate CTS. 
79 Ma instay treatments, supported by clinical guidelines8·9 include night-resting splints and local 
80 corticosteroid injection. In severe cases or those not improving with conservative treatment, 
81 surgery is considered the treatment of choice. 
82 Systematic review evidence cites two studies, both assessed as low quality, which suggest 
83 night splints may be more effective than no active treatment in the short term .10 Trials of 
84 effectiveness of splint over other non-surgical interventions in the longer term were not 
85 identified. Systematic reviews of cot1icosteroid injection 11 •12 and a subsequent trial 22 show 
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86 strong evidence of effectiveness in the short term (.:Sl month and I 0 weeks respectively) over 
87 placebo but again there is insufficient evidence of long-term effects. 
88 The comparative clinical effectiveness of corticosteroid injection and nocturnal splinting has 
89 only been investigated in two small trials. neither of which were carried out in primary care. 
90 In patients with CTS recruited from hospital clinics and confirmed by nerve conduction 
91 studies. within-group improvements in symptoms and electrophysiological findings were 
92 seen after II months of adherent use of nocturnal splints (n=28) but not after a single 
93 corticosteroid injection (n=57). 13 So et al investigated between-group comparisons at 4 weeks 
94 post-treatment, finding that a local corticosteroid injection and nocturnal wrist-splinting 
95 (n=25 participants per group) were equally effective for improving symptom severity, 
96 although finger dexterity was improved with local corticosteroid injection. 14 Here, we report 
97 the first study investigating the comparative clinical and cost-effectiveness of corticosteroid 
98 injection and night splints in primary care. 
99 The primary objective of the INSTinCTS trial (INjection versus SplinTing in Carpal Tunnel 
100 Syndrome) was to investigate whether corticosteroid injection delivered in primary care is 
101 effective in reducing symptoms and improving hand function in mild/moderate CTS when 
102 compared with a night splint worn for 6 weeks. Secondary objectives included determining 
103 the clinical and cost-effectiveness of corticosteroid injection compared with night-splinting 
104 over 6 months. 
105 Method 
106 Study design 
107 We undertook a pragmatic. multicentre, two-arm parallel group, open-label randomised 
108 clinical trial within the National Health service (NHS) in 25 centres in England, comparing a 
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109 single injection of Methylprednisolone Acetate (as 20mg of Oepo-Medrone 40mg/ml) into the 
110 carpal tunnel versus 6 weeks of night-splinting in patients with mild-moderate CTS. The full 
111 protocol has been previously published. 15 
112 The trial was approved by the National Research Ethics Service Committee North West-
113 Liverpool (UK) (reference: 13/NW /0280) and the MHRA (EudraCT number 2013-001435-
114 48). An external Trial Steering and Data Monitoring Committee were appointed. Prospective 
115 registration; C I inicaiTrials.gov (NCT0203 8452, registered 16/ I /2014 ). Current Controlled 
116 Trials (ISRCTN09392969, registered 01 /05/2014). 
117 
118 Participants 
119 We recruited participants attending general practices and community musculoskeletal clinics. 
120 Potentially eligible patients were provided with a verbal introduction to the trial and 
121 information leaflet by the general practitioner (GP) or research clinician. Patients were 
122 eligible for inclusion if they were aged 18 years and over and presented with a new episode 
123 of primary idiopathic mild/moderate CTS which had been present for more than 6 weeks. 
124 Clinical diagnosis was made by a GP or trained clinician (Physiotherapist or Occupational 
125 therapist), standardised based on presenting symptoms, clinical history and physical tests 
126 using criteria developed as part of a consensus survey of GPs from the UK Primary Care 
127 Rheumatology Society. 16 Mild CTS was defined as intermittent paraesthesia in the 
128 distribution of the median nerve and moderate as constant paraesthesia, reversible numbness 
129 and/or pain of idiopathic nature. 17 Participants with bilateral CTS designated the study hand 
130 based on the most severe symptoms. We excluded participants if; they had severe CTS, 
131 constant pain, numbness or sensory loss, thenar muscle atrophy, had received a 
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132 corticosteroid injection or night splint for CTS within the preceding 6 months, had previous 
133 surgery in the affected wrist, trauma to the affected hand requiring surgery or immobilisation 
134 in the previous 12 months, current or previous infection of the affected wrist. local or 
135 systemic sepsis or infection, inter-current iII ness, were pregnant or lactating, in receipt of 
136 anticoagulants. history of hypersensitivity to Methylprednisolone Acetate or any of its 
137 excipients, allergy to any of the splint materials, abuse of drugs or alcohol , on-going 
138 litigation. or unable to complete self-report questionnaires written in English. Written, 
139 informed consent was obtained from eligible participants who were interested in taking part 
140 in the trial. 15 Participants were screened, randomised and received the trial intervention over 
141 two appointments in those recruited via GP consultation but at one appointment in those 
142 attending community musculoskeletal clinics having been mailed trial information prior to 
143 their appointment 15• 
144 Randomisation and masking 
145 Participants were randomised to either treatment group on a 1:1 ratio using permutated blocks 
146 of sizes 2 and 4, pre-stratified by research site. Randomisation was completed by the Keele 
147 University Clinical Trial Unit's (CTU) online web or telephone randomisation service. The 
148 allocation sequence was not available to research team members. We could not mask treating 
149 clinicians or patients to treatment allocation. Analyses were conducted blind to treatment 
150 group allocation. A letter was sent to the GPs of all participants informing them of their 
151 patient's participation in the trial and their treatment allocation. 
152 Procedures 
153 Participants randomised to corticosteroid injection received one injection of 20 mg 
154 Methylprednisolone Acetate (as 20mg of Depo-Medrone from 40mg/ml) via a disposable 
155 needle (23 or 25G) and syringe which was inserted at the wrist between the proximal and 
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156 distal wrist crease to infiltrate the carpal tunnel. Injections into the palm of the hand were not 
157 permitted. Patients were treated by the diagnosing clinician and a sterile 'no-touch' technique 
158 was used without local anaesthetic. Participants were advised to wait for 30 minutes 
159 following injection and to rest the it~jected arm for 48 hours . They were given two Arthritis 
160 Research UK patient leaflets: '·Carpal tunnel syndrome'' and ''Local corticosteroid 
161 injections''. (https:/ /www .arthritisresearchuk.org/arthritis- in fom1ation/cond itions/carpa 1-
162 tunnel -syndrome/what-is-carpal-tunnel-syndrome.aspx) 
163 Participants randomised to a resting night splint received a Promedics® Beta Wrist Brace 
164 (with CE Marking) which immobilized the wrist in a neutral or slightly extended position (20 
165 degrees from neutral) intended to reduce pressure with in the carpal tunnel , to wear at night 
166 for 6 weeks. The splint was fitted according to the size of the participant's hand and arm 
167 using standard spl ints of differing sizes. Participants were shown how to fit and remove the 
168 wrist splint and were given two Arthritis Research UK patient leaflets: '·Carpal tunnel 
169 syndrome" and "Splints for atthritis of the hand and wrist". Participants were instructed to 
170 perform gentle range-of-motion exercises when removing the splint to prevent stiffness. 
171 Adherence was reinforced by verbal instruction from the clinician. 
172 No other types of therapy in either group were advised during the first 6 weeks, except for 
173 simple analgesia either prescribed or bought over the counter. To preserve the pragmatic 
174 nature of the trial, pattic ipants with bi lateral CTS were permitted treatment for the non-study 
175 hand according to normal clinica l protocols in use at the research site. 
176 Data collection/follow-up 
177 Baseline data were collected by self-complete questionnaire immediately prior to 
178 randomisation. All outcome measures were also collected at 6 weeks and 6 months by postal 
179 se If-complete questionna ire, with the exception of self-reported adverse events which were 
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180 collected in the 6-week questionnaire only. Non-responders to follow-up questionnaires were 
181 mailed a reminder postcard after two weeks. Those who did not respond after the reminder 
182 postcard were mailed a repeat questionnaire after a further two weeks. Non-responders to the 
183 repeat questionnaire reminders were telephoned by the blinded research nurse in order to 
184 collect the primary outcome measure. Participants who had not been successfully contacted 
185 by telephone after five attempts were mailed a postal minimum data questionnaire. 
186 Outcomes 
187 The primary outcome was the overall score for symptom severity and limitations in hand 
188 function on the BCTQ 18. The BCT'Q is a disease-specific questionnaire referring to a typical 
189 24-hour period in the last 2 weeks. It consists of two subscales: symptom severity scale (SSS: 
190 1 I items) and function status scale (FSS: 8 items). The primary endpoint was at 6 weeks. 
191 Secondary outcome measures included; BCTQ symptom severity and function status 
192 subscales 18• hand-wrist symptom intensity (0-10 numerical rating scale), interrupted sleep, 19 , 
193 referral for surgery. surgery. and self-reported adherence at 6-weeks. Secondary outcome 
194 measures at 6-months were; over-the-counter and prescribed analgesia, perceived benefit 
195 and satisfaction with treatment20, impact of CTS on work and activit ies, genera l health 
196 (EuroQoL EQ-50-5 L).2 1 healthcare utilisation and patient incurred costs. and use of co-
197 interventions. 
198 Twenty-two protocol deviations were reported ( 15 treatment; I el igibi I ity;3 data capture;2 
199 recruitment; l pharmacovigilance), eleven self-report adherence deviations were reported by 
200 participants. Non were assessed as serious and treatment deviations are detailed in the results 
201 . Incident adverse events from either intervention were reported and assessed using clinical 
202 case report forms. participant se lf-report in follow-up questionnaires or directly to the CTU. 
203 or to their GP. 
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204 
205 Statistical analysis 
206 Sample size 
207 We aimed to detect a 15% greater improvement on the BCTQ from an expected base line 
208 value of approximately 2·9 points (scal e 1-5, standard dev iation (S D) 1.0)22-25 in the 
209 corticostero id injection group compared to night-sp linting (i.e. a 0·9-point (30%) reduction in 
210 the injection group versus a 0-45-point ( 15%) reduction in the night splinting group, with 
211 pooled SD of 1·0, standardi sed mean di ffere nce (SM D) 0-45). Given 90% power, 5% two-
212 tail ed signifi cance and ass uming 15% loss to fo ll ow-up, 240 patients (120 in each treatment 
213 group) were required. 
214 Analysis 
215 Descriptive statistics (mean and SD or frequency counts and percentages, as appropriate) 
216 were used to summarise baseline characteristics of participants by treatment group and assess 
217 similarity of randomised participants with eligible non-participants. 
218 The primary analysis was by intention-to-treat (ITT) and was performed independently by 
219 two statisticians, who remained blind to treatment allocation up until the per-protocol 
220 analysis. Multiple imputation using chain equations26 were used to impute missing data 
221 arising from questionnaire non-response or non-completion of all items in the questionnaire. 
222 Data was assumed to be missing at random. Multiple imputation was applied to all 
223 randomised participants and the number of imputations was set at 35 . Results based on 
224 multiply-imputed data were compared to those based on complete-case analysis as a 
225 sensitivity analysis. 
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226 The primary between-group evaluation used multiple linear regression to obtain the mean 
227 between-group difference with 95% confidence intervals in the BCTQ overall score at 6 
228 weeks adjusting for age at randomisation, sex, duration of symptoms, and baseline BCTQ-
229 score. As a sensitivity analysis, ifthere was imbalance in patient characteristics between the 
230 treatment groups, the affected characteristics would be further adjusted for. 
231 Using linear and logistic regression models for continuous and dichotomous outcomes 
232 respectively, secondary analyses included between-group comparisons of the BCTQ overall 
233 score at 6 months, the BCTQ Symptom severity and function subscales and other outcome 
234 measures listed above and recorded at 6 weeks and/or 6 months. 
235 A per protocol sensitivity analysis based on self-reported adherence to night-splinting for at 
236 least 4-6 nights per week and use of a single corti costero id injection was carried out. No 
237 interim analyses were completed. 
238 Potential effect modification was investigated for (i) participants ' expectations of the likely 
239 response to co rticostero id injection or night-splinting treatments as recorded at baseline and 
240 (ii) presence of bilateral CTS, and analysed through adding moderator*treatment interactions 
241 to the models estimating the primary outcome of overall BCTS score, to provide exploratory 
242 findings regarding subgroup effects at 6 weeks and 6 months. 
243 The primary economic analysis was a cost-utility analysis, conducted from an NHS 
244 perspective to determine the cost-effectiveness of ni ght splints versus corticosteroid injection. 
245 Healthcare resource use data were obtained from self-report questionnaires at 6 months and 
246 these were valued using unit cost data obtained from the British National Formulary, Unit 
247 Costs of Health and Social Care and NHS reference costs. The cost of delivering both 
248 interventions (night splints and corticosteroid injections) was also estimated. All costs were 
249 valued at 2016/2017 prices. Outcomes were measured in quality-adjusted life years 
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250 (QALYs). Using EQ-5D 5L scores, QAL Ys over 6 months were calculated for each study 
251 participant using the area under the curve approach. Imbalances in baseline utility (EQ-50) 
252 scores between the study arms were controlled for using a multiple linear regression 
253 approach . Missing cost and EQ-50-5L scores were imputed using a multiple imputation 
254 approach. An imputation model was fitted and included 25 imputed datasets. 
255 An incremental analysis was undertaken, with differences in costs and QAL Ys expressed as 
256 an incremental cost-effectiveness ratio (JCER) of cost per additional QAL Y gained. 
257 Bootstrapping was used to quantify uncertainty, and 5000 paired estimates of mean 
258 differential costs and QAL Ys were estimated and presented on a cost-effectiveness plane. A 
259 Cost-Effectiveness Acceptability Curve (CEAC) was constructed to show the probability of 
260 injection being cost-effective across a range of possible values of willingness-to-pay for an 
261 additional QAL Y. 
262 Sensitivity analysis had four main foci. First, broader societal costs were calculated using the 
263 human capital approach to determine productivity losses due to time off work over the 6-
264 month period. Costs of absenteeism from paid work were estimated by multiplying the 
265 reported number of days off work by the average daily wage, stratified by hourly mean 
266 income according to gender, full/part-time work status and standard occupational 
267 classification (SOC 2010).27 Second, sensitivity analysis focused on estimating the cost-
268 effectiveness ofthe interventions from a healthcare perspective (including private healthcare 
269 costs) .Third, cost-utility analysis was conducted using individual-level utility scores obtained 
270 using the EQ-5D-5L questionnaire mapped back to the EQ-5D 3L valuation set as currently 
271 recommended by NICE.28 Fourth, cost-effectiveness analysis was conducted using the 
272 BCTQ. 
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273 Results were deemed statistically significant if p value<0 ·05. All analyses were performed 
274 using Stata 13 (StataCorp, 2013). 
275 Role of the funding source 
276 The trial funder had no role in study design, data collection, data ana lysis, data interpretation, 
277 or writing of the report. The corresponding author (LC) and data custodian (TMR) had full 
278 access to all data in the trial and LC had tina! responsibility for the decision to submit for 
279 publication. 
280 Results 
281 Trial participants 
282 Between I7 111Apri l 2014 and 31 st December 2016, 750 patients were seen at their GP or 
283 community musculoskeletal clin ic and assessed for elig ibil ity, of whom 405 (54·0%) fulfilled 
284 eligibility criteria (see Figure I). The most frequent reasons for ineligibility were: patients 
285 who had had cort icosteroid injection or night spli nts in the preceding 6 months (n=117, 
286 26 ·3%); severe CTS symptoms (n=54, 12·1%); inter-current illnesses (n=53. 11 ·9%). Ofthe 
287 eligible patients, 234 gave informed consent and were randomised (57·8% of 405 eligib le 
288 patients: 31.2% of750 cl inical attendees); 118 to night splint and 11 6 to injection treatment 
289 groups. Number of randomised participants from each centre ranged from 0 to 36. 
290 Demographic characteristics were similar between randomised participants (n=234) and 
291 eligible non-pa1iicipants (n= J71): mean (SO) age 52-4 (15.9) vs. 53-4 (14.7); n=80 (34·2%) 
292 vs. n=50 (29·2%) male. 
293 The majority of baseline characteristics of pa1iicipants showed minor imbalances between 
294 treatment groups. however larger imbalances were observed for (I) currently being in paid 
295 job, (2) presence of other conditions affecti ng neck, shoulders or elbow, and (3) how the hand 
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296 or wrist problems started (Table I). 217 participants returned the 6-week questionnaire, 
297 exceeding the required sample size for the primary analysis of n=200. 193 participants 
298 returned the 6-month questionnaire. Responses for the primary outcome measure were 90 · 6% 
299 (n=212) at 6 weeks and 79· 5% (n= 186) at 6 months. Participants lost to follow-up at 6 weeks 
300 tended to be you nger (responders mean (SO) 53.3 ( 15 .8) years, non-responders 40 ·6 years 
301 (I 3.4 )), more often male (n=72 (33 · 2%) vs n=8 ( 4 7 · I% )), and in employment (n= 121 
302 (55·8%) VS n= ff (64·7%)). 
303 Clinical outcomes 
304 At 6 weeks, a sign ificantly greater improvement in overall BCTQ score was seen for 
305 corticosteroid injection compared with night sp lint: (mean score 2 ·02 vs. 2 ·29; adjusted mean 
306 difference (MD) -0 ·32 (95% CJ -0-48, -0·16)). Adjusted effect estimates for BCTQ symptom 
307 severi ty subscale (MD -0 .35 (-0.53 , -0. 17)); BCTQ functional status subscale (MD -0 ·26 (-
308 0-43. -0·09)); hand pain intensity (MD -0 .97 (-1 ·64. -0· 30)) and insom ni a (odds ratio (OR) 
309 0-44 (0.22, 0·87)) at 6 weeks also favoured injection. 
310 At 6 months, further improvement in overa ll BCTQ score was seen in the night splint group, 
311 whi lst the corticosteroid injection group on average sustained improvements observed at 6 
312 weeks. (F igure 2). However. there were no statistical ly significant differences in primary or 
313 secondary outcomes between treatment groups see Table 2. 
314 No serious or unexpected adverse events were reported. In terms of expected adverse 
315 reactions; within the corticosteroid injection group four (3 · 5%) participants reported thinning, 
316 lightening or darkening of the skin at the injection site, 17 (14 · 7%) had hot flushes and 53 
317 (45·7%) experienced a more painful hand or wrist after the injection of whom 18 (34%) 
318 reported the pain lasting more than 3 days before it started to ease . In the sp lint gro up, seven 
319 (5 ·9%) were not able to wear the splints as instructed because the splints were uncomfortable. 
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320 Further adjustment of the analysis of primary outcome for the imbalanced baseline 
321 characteristics resulted in negligible changes ofthe results (-0.33 (-0 .51 , -0.16) vs . -0 ·32 (-
322 0-48, -0 · 16)) 
323 The results of the sensitivity analysis comparing effect estimates based on multiple 
324 imputation with complete-case analysis were found to be similar for all outcomes at 6 weeks 
325 and 6 months (overall BCTQ score at 6 weeks, adjusted MD -0 ·32 (-0-48, -0 · 16) based on 
326 multiple imputation vs. -0 · 36 (-0 · 54, -0 ·19) based on complete case analysis of 197 
327 participants). 
328 For the per protocol sensitivity analysis , patients whose treatment deviated from protocol 
329 were excluded. In the corticosteroid injection group three participants were excluded from the 
330 analysis as they either received an incorrect injection (n=2) or additionally to the injection 
331 wore a night splint (n= I). In the splint group, 28 participants were removed from the analysis 
332 as they: received a corticosteroid injection in addition to the night splint (n=2); wore the 
333 splint on the wrong hand (n=3); did not wear the splint for at least 4-6 nights per week (n=4); 
334 or did not provide adherence data (n= 19). Three participants switched treatment group (one 
335 participant received a splint instead the randomly allocated corticosteroid injection and two 
336 participants received a corticosteroid injection instead of the randomly allocated splint). This 
337 left 89 patients in the splint and I 14 pati ents in the inj ection arm for inclusion in the per 
338 protoco l sens it iv ity ana lys is. The results were s imilar to the ITT ana lys is with adju sted mean 
339 di ffere nces for overall BCTQ scores of -0 · 36 ( -0 · 55 ,-0· 18) at 6 weeks and 0· 05 ( -0 ·15 ,-0· 25) 
340 at 6 months. 
341 Between 6 weeks and 6 months atter randomi sati on. in the inj ect ion group 9 participants 
342 were usi ng splints; in the splint group 12 participants had rece ived an inj ection. 
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343 Exploratory, a priori defined subgroup analysis in participants with unilateral and bilateral 
344 CTS showed no statistically significant or important effect modification on the overall BCTQ 
345 score (-0·14 (-0-47, 0·19)). ·rhe adjusted mean difference for overall BCTQ score for 
346 injection versus splint was -0·25 (-0-47, -0 ·02) for those with unilateral symptoms and -0.39 
347 (-0.62, -0.15) for those with bilateral symptoms at 6 weeks. Similar results were obtained at 6 
348 months for the etfect modification ( -0 · 15 ( -0-48, 0 · 19)) and the adjusted mean difference was 
349 0·13 (-0·1 0, 0·37) for those with unilateral symptoms and -0 ·0 1 (-0·25, 0·23) for those with 
350 bilateral symptoms. 
351 The exploratory, a priori defined subgroup analysis investigating effect modification by 
352 participants' expectations regarding treatment response showed larger improvements in 
353 BCTQ scores were seen in those allocated to the intervention of their preference (n=42, -0.52 
354 (-0.93, -0.12)) compared to those who were not allocated to the intervention of their 
355 preference (n=52, -0.12 ( -0.50, 0.26)). Those who preferred to have an injection showed 
356 larger improvements (n=58, -0.60 (-0.97, -0.23)) than those who preferred a splint (n=52,-
357 0.22 (-0.60, 0.16)) or had no preference for either treatment (n=128, -0.24 (-0.44, -0.05)). For 
358 both subgroup analyses, effect modification by treatment expectations was not statistically 
359 significant. 
360 
361 Health economic outcomes 
362 Resource use, costs, outcomes (EQ-50 and QAL Ys) over 6 months associated with each 
363 intervention are presented in Supplementary files 1-3. From an NHS perspective, 
364 corticosteroid injection was more costly and more effective (cost difference £33 ·54, QAL Y 
365 difference 0.008) than night-splinting (see Figure 3). The resulting ICER was £4,193 per 
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366 QALY ga ined (Tabl e 3) w ith a 76% probabil ity of corticosteroid injection being cost-
367 effective at a w illingness -to-pay thresho ld of £20,000 per QAL Y ga ined. (F igure 3). 
368 Sensitiv ity ana lys is assess ing the broader soc ieta l costs indicated that ni ght-splinting was 
369 assoc iated with more tim e-off work and hi gher productiv ity costs (Supplementary fil e 4). The 
370 resu lts a lso show that corticosteroid inj ection was cost-effecti ve (£2,7 11 per QAL Y ga ined) 
371 from a hea lthca re perspective and also cost-effecti ve when the cross-walk tari ff was used to 
372 estim ate EQ-50 scores . Cost-effectiveness anal ys is using the BCTQ score indicates that 
373 injecti on is assoc iated with an ICER of£ 186 per unit reduction in BCTQ score 
374 (S upplementary fil e 5) . 
375 Discussion 
376 This trial is the largest randomised comparison of the short- and medium-term effectiveness 
377 of corticosteroid injection versus night splint for the treatment of CTS and the first to be 
378 conducted in a primary care setting; the arena where most patients presenting with mild or 
379 moderate symptoms are managed . The results show that at 6 weeks, across all primary and 
380 secondary outcome measures, a single injection of 20 mg Methylprednisolone Acetate led to 
381 significantly greater improvements in pain and function than night splints and that these 
382 improvements were largely sustained over 6 months which is beyond the active life of 
383 methylprednisolone acetate. As a result of further improvements in the night splint group, 
384 differences at 6 months are small and not statistically significant. The more rapid 
385 improvement associated with corticosteroid injection also leads to this treatment being more 
386 cost-effective from both an NHS and societal perspective. Our 6-month results add important 
387 and robust evidence to current inconsistent evidence of only short-term comparative 
388 effectiveness of corticosteroid injection versus night splints . 13•14 Furthermore we reported 
389 only known and expected adverse reactions. Methylprednisolone Acetate has been widely 
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390 used for many years in standard practice in both primary and secondary care and has a very 
391 well-established safety profile. 
392 There is no published minimally important clinical difference (MClD) for the overall BCTQ 
393 for a comparison between these two interventions in primary care. We proposed an MCID 
394 based on the results of two available primary care-based studies (at the time of the sample 
395 size calculation in 20 12) that separately investigated corticosteroid injections and spl ints and 
396 were therefore only indicative tor defining the threshold for our study. We achieved an II % 
397 difference in overall BCTQ scores against an anticipated 15% difference and a 0 3 effect size 
398 against an anticipated effect size of0-45. However, the pooled standard deviation of0.786 is 
399 smaller than the SD used in the sample size calculation (SD=l). Dividing the treatment effect 
400 ( -0.32) by 0. 786 gives an effect size of 0.41 which is approximately equal to the standardised 
401 difference of0.45 used in the sample size calculation. Given this and that findings were 
402 consistent across all primary and secondary outcomes with a more rapid improvement of 
403 symptoms with injection. we feel the results may be considered sufficiently clinically 
404 important by patients with mild-severe symptoms ofCTS. 
405 There is no consensus on the optimal dose or choice of corticosteroid to inject for CTS. One 
406 study based in secondary care 29 found that higher doses of corticosteroid (60 mg 
407 Methylprednisolone Acetate) resulted in more patients being free from important symptoms 
408 than lower doses (20 or 40 mg) at 6 months (success rates: 60mg, 73%; 40mg, 56%; 20mg, 
409 53%) but there was no evidence of longer-term benefits at 12 months. In a second study, 
410 again in secondary care and in patients where sp linting had already failed, improvements in 
411 symptom severity scores at 10 weeks were also greater in patients who received 80 mg and 
412 40 mg of methylprednisolone than in those who received placebo (difference in change from 
413 baseline, -0.64 [95% CL -1.06 to -0.21; p value= 0.003] and -0.88 [CL -1.30 to -0.46; p value 
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414 < 0.00 I]. respectively), but there were no significant differences at I year.22 Our study is 
415 informative in that it shows that a single injection of a relatively low dose of 20 mg 
416 Methylprednisolone Acetate (which reflects a consensus regarding usual practice for 
417 admin istering corti costeroid injection for CTS in primary care) produced a more rapid 
418 improvement of mild/moderate symptoms compared to using night splints. 
419 Landmark-guided (or blind) corticosteroid steroid injection was used in the trial as this is the 
420 standard technique used in primary care where access to ultrasound is usually limited. 
421 Unguided corticosteroid injections have been shown to be of comparable efficacy to 
422 ultrasound-guided injections in reducing symptoms, and improving function and 
423 electrophysiological findings in CTS. 30 
424 CTS is routinely classified as mild, moderate or severe although criteria for this 
425 categorisation are not well established and there is lack of an accepted "gold standard" for 
426 diagnosis particularly in relation to the inclusion of electrophysiological tests. In some 
427 countries, including the UK, primary care access to nerve conduction studies is variable or 
428 limited. As such these investigations are usually reserved for indeterminate diagnoses and are 
429 not always required routinely in primary care for mild/moderate cases to guide decisions 
430 regarding initial conservative treatments . 7 For the purposes of this trial we felt it was 
431 important to develop a tool to standardise the diagnosis of CTS presenting in primary care. A 
432 full description of the design of this tool is published elsewhere. 16 
433 Strengths of our trial include the large sample size, length of follow-up and full health 
434 economic ana lysis. In order to answer our pragmatic research quest ion regarding comparative 
435 effectiveness it was crucial to conduct the trial in a setting very close to routine primary care. 
436 To opti mize the generali sability of the findings. maximise recruitment and achieve realistic 
437 recruitment targets, we decided to also recruit from community-based musculoskeletal 
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438 services which receive direct referrals from multiple GPs who themselves do not inject CTS 
439 patients. The characteristics of our trial population were similar to eligible non-participants, 
440 which strengthens the generalisability of our findings, with the majority of participants 
441 experiencing their first episode of CTS with symptoms for at least 3 months. Trial 
442 participants and clinicians were not blinded to treatment allocation, but this is common to 
443 many trials of non-pharmacological interventions, and was inherent to the research question 
444 and pragmatic design of our trial. Limitations of our trial include the lack of a no-treatment 
445 control group, or a group receiving both interventions, which is not uncommon in primary 
446 care. We felt it was important to offer treatment to all participants consulting for 
447 mild/moderate symptoms, and adding a third arm would have increased sample size and 
448 compromised the feasibility of the trial in a primary care setting. A clinical assessment was 
449 not included at follow-up so we are unable to comment on changes in clinical findings . The 
450 recruitment period ended prior to randomising the target of240 participants. Although this 
451 did not compromise statistical power due to high follow-up rates, it meant the block 
452 randomisation sequence was not completed, leading to a minor imbalance in the number of 
453 participants in the treatment groups (n=2). 
454 In conclusion a single corticosteroid injection shows superior clinical effectiveness at 6 
455 weeks, and is cost-effective over 6 months compared with night-resting splints, making it the 
456 treatment of choice for rapid and sustained symptom response in mild/moderate CTS 
457 presenting in primary care. These findings inform evidence-based treatment choices for GPs, 
458 and clinicians in community musculoskeletal services. 
459 Research in context 
460 Evidence before this study 
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461 Before this study, there was no robust evidence of the comparative clinical or cost-
462 effectiveness of night splints and corticosteroid injection in the medium term or in a primary 
463 care population. At the time of designing the INSTINCTS trial (2009-20 12), systematic 
464 review evidence for the treatment of Carpal Tunnel Syndrome (CTS) identified only one, 
465 small trial, conducted in a secondary care setting, of head-to-head comparison for two of the 
466 mainstay interventions (corticosteroid injections and night-resting splints) used in primary 
467 care for this syndrome. A lack of robust evidence of clinical effectiveness beyond the short 
468 term for both interventions in any settings was also identified with most existing trials 
469 conducted in secondary care where patients are likely to have CTS that is of longer duration 
470 and less responsive to conservative management. No trials had assessed cost-effectiveness of 
471 either intervention. 
4 72 Added value of this study 
473 Our study is the largest trial yet undertaken of corticosteroid injection compared with night 
474 splints for CTS. We have shown significant short-term and sustained improvements for 
475 corticosteroid injections compared with night splints, with no safety issues. This is the first 
476 study to carry out a full economic assessment and demonstrate that both interventions are 
477 relatively inexpensive, with corticosteroid injection proving cost-effective over the use of 
478 night splints over 6 months. 
479 Implications of all the available evidence 
480 In a primary care where most treatment for mild/moderate CTS is undertaken, the evidence 
481 now shows that a corticosteroid injection is the cost effective treatment of choice for rapid 
482 and sustained symptom response compared with night splints. These findings provide 
483 evidence to support treatment decision-making for policy makers, payers (commissioners) 
484 GPs, and clinicians in musculoskeletal services and offer choice to patients. 
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508 Figure I : Consort flow diagram 
509 
510 
Assessed for eligibility 
N=750 
Excluded 
N=S16 
Not diagnosed with CTS (n=71) 
Diagnosed with CTS (n=445) 
- Not met inclusion/exclusion criteria (n=268) 
- GP decision patient not eligible (n=6) 
- No reason given (n=34) 
- Unwi lling to receive intervention (n=123) 
- Unwi lling to comply with fol low-up (n= lO) 
- Other (n=4) 
I 
Allocated to treatment night splint 
(n=118) 
Response rate 99 .2% 
-Completed questionnaire (n=117) 
- Did not respond (n=l) 
I 
Mai led 6 week questionnaire (n=118) 
Response rate 92.4% 
-Completed questionnaire (n=109) 
- Did not respond/refused (n=7) 
- Patient self-withdrawal (n=2) 
I 
Mailed 6 month questionnaire (n=116) 
Response rate 83.6% 
-Completed questionnaire (n=96) 
Randomised 
N=234 
I 
I 
Allocated to treatment corticosteriod injection 
(n=116) 
Response rate 97.4% 
-Completed questionnaire (n=113) 
- Did not respond (n=3) 
I 
Mailed 6 week questionnaire (n=116) 
Response rate 93 .1% 
-Completed questionnaire (n=108) 
- Did not respond/refused (n=8) 
- Patient self-withdrawal (n=O) 
I 
Mailed 6 month questionnaire (n=116) 
Response rate 82.8% 
-Completed questionnaire (n=96) 
-Completed questionnaire & withdrawn (n=l) -Did not respond/refused (n=17) 
- Did not respond/refused (n=17) - Patient self-withdrawal (n=3) 
- Patient self-withdrawal (n=2) 
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Table 1. Baseline characteristics of randomised patient 
Characteristic 
Injection Night Splinting 
N= ll6 
N= l18 
Demographics 
Age (Range : 21 , 92 years) (Mean (SD)) 52.6(17.0) 52.2 ( 14.9) 
Sex 
Male 43 (37.1) 37(31.4) 
Female 73 (62.9) 81 (68.6) 
PastCTS 
First time diagnosed with CTS 
Yes 97 (83.6) I 02 (86.4) 
No 16 (13 .8) 15 (12.7) 
Missing 3 (2.6) I (0.8) 
Number of times previously had CTS 
N/A 97 (83 .6) I 02 (86.4) 
II (9 .5) 8 (6.8) 
2 I (0 .9) I (0 .8) 
3 0 (0) 0 (0) 
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>3 3 (2 .6) 4 (3 .4) 
Missing 4 (3.4) 3 (2.5) 
Treatments for previous CTS for either hand 
N/A 97 (83 .6) 102 (86.4) 
None 5 ( 4.3) 8 (6 .8) 
Steroid injection 3 (2 .6) 4 (3 .4) 
Wrist splints 7 (6.0) 4 (3.4) 
Carpal tunnel decompression (surgery) 3 (2.6) 2 ( 1.7) 
Ultrasound I (0.9) I (0 .8) 
Exercises 0 (0) 0 (0) 
Vitamin supplements 0 (0 .0) I (0.8) 
Changes in the work place 0 (0) 0 (0) 
Other (Physio) 1 (0.9) 0 (0) 
CurrentCTS 
Which problematic hand or wrist 
Right 36 (31 .0) 37 (31.4) 
Left 19 (16.4) 20(16.9) 
Both 57 (49.1) 59 (50.0) 
Missing 4 (3.4) 2 ( 1.7) 
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If both hands problematic, which hand is worse 
N/A 55 (47.4) 57 (48.3) 
Right 25 (21.6) 24 (20.3) 
Left 13 (11.2) 19 (16.1) 
No difference 7 (6.0) 3 (2 .5) 
Missing 16(13.8) 15 (12.7) 
Duration of hand or wrist problems 
<3 months 19(16.4) 17 (14.4) 
3-6 months 37 (31.9) 33 (28 .0) 
6 months - 1 year 22(19.0) 27 (22.9) 
> I year 34 (29.3) 39 (33.1) 
Missing 4 (3.4) 2 (1.7) 
How did hand or wrist problems start 
Suddenly: symptoms developed quickly within a few days 33 (28.4) 17(14.4) 
Gradually: symptoms developed more slowly over weeks to months 79 (68.1) 99 (83.9) 
Missing 4 (3.4) 2 ( 1.7) 
Particular position causes hand or wrist problems 
Yes 50(43.1) 62 (52.5) 
No 62 (53.4) 54 (45 .8) 
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Missing 4(3.4) 2 (I. 7) 
Currently taking pain relief for hand or wrist problems 
Yes 36 (31 .0) 34 (28 .8) 
No 77 (66.4) 83 (70.3) 
Missing 3 (2.6) l (0.8) 
--
Employment 
In a current paid job 
Yes 58 (50.0) 74 (62.7) 
No 55 (47.4) 42 (35.6) 
Missing 3 (2 .6) 2 (I. 7) 
If not in current paid job, describe current situation 
N/A 58 (50.0) 74 (62.7) 
Retired 38 (32.8) 29 (24.6) 
Student 3 (2 .6) I (0.8) 
Looking after children/home 12 (10 .3) 9 (7 .6) 
Unemployed 3 (2 .6) 7 (5.9) 
Voluntary worker 2 ( l. 7) 0 (0 .0) 
Missing 3 (2.6) 2 (1.7) 
Treatment expectations 
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Which treatment would you prefer 
Strongly prefer wrist injection 
Somewhat prefer wrist injection 
No preference 
Somewhat prefer night splints 
Strongly prefer night splints 
Missing 
If you received wrist injection would you expect your symptoms to improve 
Yes 
No 
Not sure 
Missing 
If you received a night splint, would you expect your symptoms to improve 
Yes 
No 
Not sure 
Missing 
Quality of life 
Been bothered by feeling down, depressed or hopeless 
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13 (I 1.2) 
II (9.5) 
65 (56.0) 
12 (10.3) 
6 (5.2) 
9 (7.8) 
69 (59.5) 
0 (0.0) 
39 (33.6) 
8 (6.9) 
46 (39.7) 
3 (2.6) 
58 (50 .0) 
9 (7 .8) 
13(11.0) 
21 (17.8) 
60 (50 .8) 
8 (6.8) 
I 0 (8 .5) 
6 (5 .1) 
70 (59.3) 
2 ( 1.7) 
41 (34 .7) 
5 (4 .2) 
40 (33 .9) 
4 (3 .4) 
69 (58 .5) 
5 ( 4.2) 
Yes 47 (40 .5) 39(33 .1) 
No 66 (56.9) 78(66.1) 
Missing 3 (2 .6) I (0 .9) 
Been bothered by little interest or pleasure in doing things 
Yes 39 (33 .6) 33 (30.0) 
No 74 (63 .8) 83 (70 .3) 
Missing 3 (2.6) 2 (1.7) 
General health 
Diagnosed with hypothyroidism 
Yes 5 ( 4.3) 9 (7.6) 
No 108 (93.1) 107 (90.7) 
Missing 3 (2.6) 2 ( 1.7) 
Diagnosed with diabetes 
Yes 13(11.2) 8 (6 .8) 
No 99 (85 .3) 109 (92.4) 
Missing 4 (3.4) I (0 .8) 
Any other conditions affecting neck, shoulders or elbows 
Yes 45 (38.8) 28 (23 .7) 
No 68 (58 .6) 88 (74.6) 
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Missing 3 (2 .6) 2 ( 1.7) 
Had pain anywhere else apart from your hand or wrist 
Yes 74 (63 .8) 72 (61.0) 
No 39 (33.6) 45 (38.1) 
Missing 3 (2 .6) I (0.8) 
Last time you were free of pain anywhere 
<3 months ago 22 (19 .0) 20 (16.9) 
3-6 months ago 13(11.2) 19 (16.1) 
6 months - I year ago 9 (7 .8) 23 (19 .5) 
1-3 years ago 38 (32.8) 23 (19.5) 
>3 years ago 31 (26.7) 32(27.1) 
Missing 3 (2.6) I (0 .8) 
On average how often do you drink alcohol 
Daily or most days II (9.5) II (9.3) 
Once or twice a week 38 (32 .8) 45 (38 .1) 
Once or twice a month 25 (21.6) 22(18.6) 
Once or twice a year 16 (13 .8) 18 (15 .3) 
Never 23 (19.8) 21 (17.8) 
Missing 3 (2 .6) I (0 .8) 
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What is your current smoking status 
Never smoked 55 (47.4) 55 (46.6) 
Previously smoked 39 (33.6) 48 (40.7) 
Current smoker 19 (16.4) 13( 11.0) 
Missing 3 (2.6) 2 ( 1.7) 
Body mass index (mean (SD)) 30.2 (7 .6) 30.5 (7 .5) 
Data are N(%) unless otherwise stated. Based on original data (N=234) 
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Table 2 Comparative treatment effectiveness at 6 weeks and 6 months 
Mean (SD) Regression analysis* 
Corticosteroid injection Night splinting Adjusted mean difference (95% p value 
CI) 
N=116 N=I18 
Overall BCTQ symptom severity and 
functiona11imitations 
Baseline 2.69 (0.70) 2.65 (0.62) 
6 weeks 2.02 (0.81) 2.29 (0.75) -0.32 ( -0.48, -0.16) <0.001 
6 months 2.15 (0 .79) 2.06 (0.73) 0.06 (-0.11, 0.23) 0.499 
BCTQ Symptom severity scale 
Baseline 2.96 (0.66) 2.91 (0.61) 
6 weeks 2.12(0.84) 2.43 (0 .76) -0.35 (-0.53, -0.17) <0.001 
6 months 2.33 (0.86) 2.18 (0.75) 0.13 (-0.07, 0.33) 0.209 
BCTQ Functional limitations 
Baseline 2.32 (0.92) 2.28 (0 .84) 
6 weeks 1.88 (0 .88) 2.09 (0 .86) -0.26 ( -0.43 , -0 .09) 0.003 
6 months 1.91 (0.84) 1.89 (0.84) <0.0 I (-0.18, 0.17) 0.957 
Hand-wrist pain intensity 
Baseline 6.33 (2.05) 6.12(2.21) 
6 weeks 3.42 (2 .77) 4.28 (2 .73) -0.97 ( -1.64, -0.30) 0.005 
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6 months 4.32 (3.26) 3.46 (3.01) 
N (%) 
Insomnia due to hand or wrist problems 
Baseline 70 (60.6%) 60 (50.6%) 
6 weeks 33 (28.2%) 45 (38.3%) 
6 months 37 (31.9%) 32 (27.2%) 
Referral to surgery 
6 weeks 4 (3.2%) 5 (4.6%) 
6 months 22 (18.6%) 14(11.9%) 
Surgery 
6 weeks 2(1.3%) 2(1.8%) 
6 months 17(14.3%) 13(11.1%) 
Herbal remedies & vitamin use 
6 months 7 (6.4%) 7 (6.0%) 
Over the counter pain medication 
6 months 34 (29.5%) 30 (25.3%) 
Prescribed pain medication 
6 months 20 (17.5) 12 (10.6%) 
Based on multiply imputed data; 234 participants were analysed ( 116 in corticosteroid injection arm, 118 to night splinting) 
NULL- unable to perform analysis due to low numbers 
*Regression analysis adjusted for baseline score (if available), sex, age, and duration of symptoms; SD=standard deviation; 
Page 33 of 45 
0.79 (-0.02 , 1.59) 0.055 
Odds ratio (95% Cl) p value 
0.44 (0.22, 0.87) 0.018 
1.12 (0.55 , 2.20) 0.755 
NULL NULL 
1.66 (0.73 , 3.77) 0.227 
NULL NULL 
1.28 (0.41 , 3.98) 0.664 
1.43 (0.28, 7.34) 0.664 
1.42 (0.63 , 3.18) 0.399 
1.99 (0.70 , 5.66) 0.197 
Table 3 Cost-utility analysis (Injection versus splinting) 
Injection Night splint Difference (CI) ICER 
(n= ll8) I 
(n=Il6) 
Mean costs (SD) £346.78 (467.97) £313.24 (480.84) £33 .54 (-94.57, 145 .59) £4,193 per QAL Y gained 
Mean QALYs" 0.404 0.396 0.008 ( -0 .0 I , 0.02) 
" Adjusted for baseline utility 
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Supplementary file 1: Mean (SD) NHS resource utilisation over 6 months (Complete case analysis) 
GP visits 
Nurse visits 
Physiotherapist visits 
Surgeon visit) 
Rheumatologist visit 
Acupuncturist visit 
Occupational therapist visit 
Other health professionals 
X-ray 
Ultrasound 
MRl scan 
Blood test 
Injection 
N=95 
0.421 (0.807) 
0.026 (0 .207) 
0.074 (0.550) 
0.126 (0.419) 
0.137 (1.048) 
0 
0.021 (0.144) 
0.042 (0.249) 
0.011 (0.103) 
0 
0.021 (0.144) 
0.021 (0.205) 
Night splint 
N=96 
Health Professionals 
0.656 (1.204) 
0.051 (0 .389) 
0.135 (0.690) 
0.135 (0.450) 
0.125 (0 .441) 
0.042 (0.408) 
0.083 (0.496) 
0.135 (0.473) 
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Investigations and interventions 
0.052 (0.266) 
0.021 (0 .144) 
0.010 (0.102) 
0.104 (0.571) 
Difference (CI) 
-0.24 ( -0 .54, 0.05) 
-0.03 (-0 .16, 0.04) 
-0.06 (-0 .24, 0.11) 
-0.009 (-0 .14, 0.10) 
0.01 (-0 .15, 0.35) 
-0.04 (-0.14, 0) 
-0.06 ( -0.19, 0.02) 
-0.09 (-0.20, 0.01) 
-0 .04 (-0.11, 0.01) 
-0.02 (-0 .06, 0) 
0.01 ( -0 .02, 0.05) 
-0.08 ( -0.20, 0.02) 
Nerve studies 
Wrist splint 
Wrist injection 
Wrist exercise 
0.074 (0 .300) 
0.063 (0.245) 
0.295 (0 .503) 
0.021 (0.144) 
0.073 (0.261) 
0.250 (0.481) 
0.208 (0 .501) 
0.020 (0 .144) 
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0.001 ( -0 .06, 0.07) 
-0.19 (-0 .24, -0 .06) 
0.09 ( -0.05, 0.18) 
0.001 (-0.35 , 0.03) 
Supplementary file 2: Mean (SD) NHS costs over 6 months(£) (Complete case analysis) 
GP visits 
Nurse visits 
Physiotherapist visits 
Surgeon visit 
Rheumatologist visit 
Acupuncturist visit 
Occupational therapist visit 
Other health professionals 
x-ray cost 
Blood test 
Ultrasound cost 
MRl scan cost 
Surgery cost 
Additional Wrist splint cost 
Additional Wrist Injection cost 
Wrist exercise cost 
Nerve conduction cost 
Prescribed medication cost 
Intervention cost• 
Injection 
N=95 
12.2 1 (23 .39) 
0.57 (4.11) 
3.32 (24.77) 
8.21 (27 .22) 
6.15 (47 .16) 
0 
0.88 (6 .06) 
1.63 (9 .24) 
0.36 (3 .54) 
0.13 (1.23) 
0 
3.45 (23 .67) 
132.12 (470.92) 
3.15(12.23) 
15 .62 (26.63) 
13 .26 (22 .62) 
12.16(49.5 7) 
1.30 (5 .61) 
138.94 (69 .17) 
Night splint 
N=96 
19.03 (34 .91) 
1.13 (7 .75) 
6.09 (31.05) 
8.80 (29.25) 
5.63 (19 .86) 
1.88 (18 .37) 
3.50 (20 .81) 
2.14(12.31) 
Health Professionals 
Difference (CI) 
-6.82 (-15.10, 1.15) 
-0.56 ( -2.81 , 0.93) 
-2.78 (-11.61, 4.72) 
-0.59 (-9.23 , 7.40) 
0.52 (-6.89, 13 .17) 
-1.88 (-6.99, 0) 
-2 .62 (-7.67, 0.92) 
-0 .51 (-3.68, 2.42) 
Investigations and interventions 
1.80 (9 .19) 
0.63 (3.43) 
1.14 (7.90) 
1.71 (16.74) 
112.06 (436.29) 
12.5 (24.06) 
11.04 (26 .55) 
9.38 (22.54) 
12.03 (43.16) 
1.92 (7 .68) 
94.02 (65 .66) 
-1.43 (-3.72 , 0.22) 
-0.50 (-1.49, 0.05) 
-1.14 (-3.16, 0) 
1.74 (-3.52, 8.28) 
20.05 (-101.69, 160.05) 
-9.35 (-5.55, -1.68) 
4.5 8 ( -2.81, 11.36) 
3.89 (-2.51, 10.14) 
0.13 (-12.86, 14.47) 
-0.61 (-2.83 , 0.99) 
44.92 (24.83, 62.13) 
Total Costs (complete cases) 
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Total cost (NHS) 353.48 (512.85) 306.42 (524.51) 47.06 (-104.84, 187.31) 
Total Costs (imputed analysis) 
N= ll6 N=118 
Total cost (NHS) 346.78 (467.97) 313 .24 (480.84) 33.54 (-94.57, 145.59) 
a Costs associated with the intervention took into account whether the patient was seen by a GP or physio and whether they were seen in the GP practice or interface clinic. Unit costs associated with the 
intervention are as follows: Injection by GP in interface clinic (£ 191 ); Injection by GP in GP practice (£207); Injection by Physio in interface clinic (£53); Injection by Physio in GP practice (£69); Splinting by GP 
in interface clinic (£188); Splinting by GP in GP practice (£204); Splinting by Physio in interface clinic (£50); Splinting by Physio in GP practice (£66) 
Page 38 of 45 
Supplementary file 3: Mean (SD) Health outcomes over 6 months 
EQ-5D baseline 
EQ-5D 6 weeks 
EQ-5D 6 months 
QAL Y s (Unadjusted) 
QALYs (Adjusted)" 
a Adjusted for baseline utility 
Injection 
N= 116 
0.764(0.190) 
0.794 (0 .200) 
0.819 (0 .161) 
0.400 (0 .083) 
0.404 
Night splint 
N= l18 
0.784(0.190) 
0.781 (0 .205) 
0.826 (0.174) 
EQ-5D 
Total QALYs 
0.399 (0 .086) 
0.396 
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Difference (C I) (Injection - Night 
splint) 
-0.02 (-0 .07, 0.03)) 
0.01 (-0 .04, 0.06) 
-0.007 (-0 .05 , 0.04) 
0.00 I ( -0.02, 0.02) 
0.008 ( -0.01 ' 0.02) 
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Supplementary file 4: Sensitivity analysis: time off work over 6 months. Mean (SO) per patient (Complete cases) 
Performance at work 6 weeks a 
Performance at work 6 months a 
Days off-work 6 weeks 
Days off-work 6 months 
Productivity costs b 
Injection 
N=95 
0.18 (0 .95) 
0.87 (1.86) 
0.07 (0 .51) 
0.58 (3 .88) 
50.42 (31 0.99) 
Night splinting 
N=96 
Broader societal costs 
0.26 (1.25) 
1.32 (2.44) 
0.05 (0 .30) 
1.42 (7 .85) 
93.76 (574.85) 
Difference (CI) (Injection- Night 
splint) 
-0 .14 (-0.47, 0.18) 
-0 .36 ( -0 .88, 0.16) 
0.02(-0.10, 0.14) 
-0.84 (-2.64, 0.94) 
-43.34 (-202.72, 71.34) 
-33.70 (-167.36, 99.96) c 
a Mean performance at work on a scale of 0 to I 0 where 0 indicates work performance not affected b Productivity costs obtained from days off-work at 6 weeks and 6 months 
c Adjusted for employment at baseline 
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Supplementary file 5: Sensitivity analysis 
Mean cost difference over 6 months 
(Injection- Night splint) 
£21.69 
£33.54 
Mean cost difference over 6 months 
(Injection- Night splint) 
£33.54 
Mean QALY difference over 6 months 
(Injection- Night splint) 
Healthcare perspective 
0.008 
EQ-50 using cross-walk tariff (NHS perspective) 
0.004 
Cost-effectiveness using the Boston CTS (NHS perspective) 
Mean Boston CTS score difference over 6 months 
(Injection - Night splint) 
-0 .18a 
a overall Boston CTS score over 6 months controlling for baseline score, age and sex 
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ICER 
£2,711 per QALY gained 
£8,385 per QAL Y gained 
ICER 
£186 per unit reduction in Boston CTS score 

